nadplus.digital

What is known about NAD+ IV infusions?

NAD+ infusions are increasingly offered1. A systematic review found no suitable study on their health benefit2. Symptoms during the infusion have been reported1.

October 2026

What are the key points in brief?

Which studies exist on NAD+ infusions?

The 2026 systematic review found no suitable outcome study that tested NAD+ itself as an infusion or injection for anti-aging or wellness. It counted a pilot study on the fate of infused NAD+ in the body, which had no suitable clinical endpoints, as background only2.

This pilot study measured plasma and urine during a six-hour NAD+ infusion. In the first two hours, the NAD+ level in plasma did not rise. In that time, NAD+ was cleared quickly and completely from the plasma3.

The authors of a 2026 study write that commercial facilities increasingly offer NAD+ infusions although safety and efficacy have been little studied1.

Which symptoms were reported during infusions?

A retrospective analysis of treatment records from a commercial facility compared infusions of NAD+ and of NR on four consecutive days1.

This is a retrospective pilot study. The authors speak of preliminary results1.

Which questions can you ask before an infusion offer?

If you have been offered an NAD+ infusion, these questions can help:

Common causes of persistent fatigue can be narrowed down with a conversation, an examination and simple lab values4. The five-step preparation helps with the appointment.

If you are pregnant or breastfeeding, take medication regularly or have or had cancer, the page Does NAD+ have side effects? has notes on this.

Which sources does this page rely on?

  1. Reyna K et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. DOI: 10.3389/fragi.2026.1652582

    The study compares how well NAD+ and NR infusions on four consecutive days are tolerated. It is a retrospective review of treatment records with 30 days of follow-up. NAD+ was more often linked to marked discomfort during the infusion and longer infusion times, and symptoms resolved once the infusion ended.

  2. Gallagher C, Emmanuel OO (2026). NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. DOI: 10.1016/j.arr.2026.103057

    The review asks what studies on NAD+ products show for ageing and well-being. It systematically assesses 113 studies, 33 of them in humans. NR and NMN may raise NAD levels and appear well tolerated, while a clinical benefit remains open, and suitable trials of NAD+ infusions were lacking.

  3. Grant R et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. DOI: 10.3389/fnagi.2019.00257

    The study followed what happens to NAD+ in plasma and urine during a six-hour infusion. It is a pilot study in humans. Plasma NAD+ did not rise during the first two hours, which may indicate rapid breakdown in the body.

  4. Maisel P, Baum E, Donner-Banzhoff N (2021). Fatigue as the Chief Complaint. Deutsches Ärzteblatt International. DOI: 10.3238/arztebl.m2021.0192

    The paper summarises how family doctors may assess persistent fatigue. It is a review based on a literature search. Its authors suggest that history, physical examination and simple laboratory tests may usually be enough, with further tests mainly when other findings point that way.